Clinical trials: Healthy Postmenopausal Women
Postmenopausal Osteoporosis, Multiple Sites
Safety Study of an Oral Vitamin D Analog in Postmenopausal Women
Determine the safety of 2MD, a vitamin D analog, when administered orally once daily for 28 days in healthy normal postmenopausal women.
- Trial name
- NCT01969656
- Testing
- 2MD, Calcitriol
- Sponsor
- Deltanoid Pharmaceuticals
Menopause
A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy
This is a two-arm, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy of Enjuvia 0.3 mg tablets for the treatment of moderate to severe symptoms of vulvovaginal atrophy in postmenopausal…
- Trial name
- NCT00196378
- Testing
- Synthetic Conjugated estrogens, B
- Where
- 38 sites in United States
- Volunteers
- 300 people
- Sponsor
- Duramed Research
Postmenopause
Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women
The purpose of the study is to evaluate the safety and efficacy of new tablet formulations of Premarin®/medroxyprogesterone (MPA).
- Trial name
- NCT00543634
- Testing
- Premarin/MPA, Provera 10 mg
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Breast Cancer Survivors, Postmenopause
Resistance-type Exercise Training in Postmenopausal Women Survivors of Breast Cancer
Background: In postmenopausal women, an alteration in body composition occurs as a consequence of the secretion of low levels of serum estrogens by the ovaries.
- Conditions
- Breast Cancer Survivors, Postmenopause, Resistance Training
- Trial name
- MUSCLE-CLIM (NCT05690295)
- Testing
- Prolonged resistance-type exercise training
- Where
- Chile
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Universidad de La Frontera
Healthy Volunteers
A Study of ACE-2494 in Healthy Subjects
The purpose of the study is to assess safety, tolerance, pharmacokinetic, and pharmacodynamics of single doses of ACE-2494 in healthy postmenopausal women.
- Trial name
- NCT03478319
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Healthy Volunteers
Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men
The primary objective is to assess the safety and tolerability of REGN2477 alone and combined with REGN1033. The secondary objectives are to: Assess the effect of REGN2477 alone, REGN1033 alone, and REGN2477 + REGN1033 in…
- Trial name
- NCT02943239
- Testing
- REGN1033, REGN2477
- Where
- 2 sites in New Zealand
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Healthy
Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women
This study will assess if itraconazole will affect the blood levels of Duavee when they are given together. This study will also assess if a subject's body size affects the blood levels of Duavee.
- Trial name
- CE/BZA (NCT02100553)
- Testing
- CE/BZA, Itraconazole
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Postmenopausal Symptoms
Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women
The purpose of this study is to assess the pharmacokinetics (absorption, breakdown and elimination from the body), safety and tolerability of Brisdelle (paroxetine mesylate) Capsules 7.5 mg when given as a single dose and…
- Trial name
- N30-005 (NCT01829919)
- Testing
- Brisdelle (paroxetine mesylate)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Noven Therapeutics
Postmenopausal, Osteopenia
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)
The primary objective of this study was to assess the safety, tolerability, and immunogenicity potential of romosozumab following multiple subcutaneous (SC) administrations in healthy men and postmenopausal women with low bone…
- Trial name
- NCT01825785
- Testing
- Romosozumab
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Amgen
Breast Cancer
IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of IH636 grape seed extract may prevent breast cancer.
- Trial name
- NCT00100893
- Testing
- IH636 grape seed proanthocyanidin extract
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Healthy Postmenopausal Women
Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F and T121E02F in Healthy Postmenopausal Women
THAR2011-1 is a Phase I, single dose, open-label dose-escalation study to determine the safety, absolute bioavailability, dose proportionality, and pharmacokinetics of T121 in healthy postmenopausal women.
- Trial name
- NCT01721993
- Testing
- T121, Zoledronic acid
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Thar Pharmaceuticals, Inc
Healthy, Postmenopausal
AZD1981 Bioavailability Study of Intravenous (IV) and Oral Formulations
The primary objective is to investigate the pharmacokinetics of AZD1981 given in different formulations and to measure renal clearance
- Conditions
- Healthy, Postmenopausal, Surgically Sterile Women
- Trial name
- NCT00918398
- Testing
- AZD1981
- Where
- Sweden
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Normal Hepatic Function, Impaired Hepatic Function
Effect of Hepatic Impairment on LDE225..
This study is to evaluate the pharmacokinetics and safety of 800 mg of LDE225 in subjects with impaired hepatic function and healthy subjects with normal hepatic function.
- Trial name
- NCT01764776
- Testing
- LDE225
- Where
- 5 sites in United States, Belgium and 3 more
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy Postmenopausal Women, Absorption
A Clinical Study to Evaluate the Absorption, Metabolism, and Excretion of Oral [14C]GS1-144 in Healthy Postmenopausal Female Participants
This is a single-center, non-randomized, open-label, single-dose clinical PK study in healthy postmenopausal female participants.
- Conditions
- Healthy Postmenopausal Women, Absorption, Metabolism, Excretion
- Trial name
- NCT07537231
- Testing
- [14C]GS1-144
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Healthy Subjects
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESN364 in Healthy Japanese Male and Pre- and Post-menopausal Female Subjects
The purpose of this study is to evaluate the safety and tolerability of single and multiple oral doses of ESN364 in healthy Japanese male and pre- and post-menopausal female subjects.
- Trial name
- NCT03436849
- Testing
- ESN364
- Where
- Japan
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Healthy, Postmenopausal
Progesterone Reduces Wakefulness in Sleep EEG and Has no Effect on Cognition in Healthy Postmenopausal Women
Sleep is impaired in postmenopausal women (difficulty falling asleep, frequent awakenings). Progesterone prompted benzodiazepine-like effects on sleep EEG in young normal male subjects.
- Trial name
- NCT00530582
- Testing
- progesterone
- Where
- Germany
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Max-Planck-Institute of Psychiatry
Breast Cancer, Endometrial Cancer
Genistein in Preventing Breast or Endometrial Cancer in Healthy Postmenopausal Women
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of genistein may be effective in preventing breast or endometrial cancer.
- Trial name
- NCT00099008
- Testing
- Genistein
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Estrogen Replacement Therapy
Study Comparing Bioavailability of 3 New Formulations of Premarin/MPA With Premarin/MPA (PREMPRO) Reference Formulation
This study will compare the bioavailabity of three new investigational combination formulations of Premarin and medroxyprogesterone acetate (MPA) with a currently marketed formulation of Premarin and MPA, Prempro™.
- Trial name
- NCT00401219
- Testing
- conjugated estrogens/progestin (MPA)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Healthy
Fasting Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg
The objective of this study was to investigate the bioequivalence of Mylan's letrozole 2.5 mg tablets to Novartis' Femara® 2.5 mg tablets following a single, oral 2.5 mg (1 x 2.5 mg) dose administered under fasting conditions.
- Trial name
- NCT00648063
- Testing
- Letrozole Tablets 2.5 mg, Femara® Tablets 2.5 mg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Healthy
Study to Evaluate 3 Dosages of Estetrol After 28 Days Administration in Healthy Postmenopausal Women
Estetrol is a natural compound that is produced by the fetus during fetal life and circulates in the unborn child and the mother. It is an estrogenic compound.
- Trial name
- NCT00163033
- Testing
- estetrol
- Where
- Netherlands
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Pantarhei Bioscience